阿德福韦酯与苦参素联合治疗HBeAg阳性慢性乙型肝炎的疗效观察

目的:观察和比较单用阿德福韦酯与阿德福韦酯联合苦参素治疗HBeAg阳性慢性乙型肝炎的疗效。方法:将2005年12月至2007年3月收治的63例HBeAg阳性慢性乙型肝炎患者分成联合组和单用组。联合组31例,同时使用阿德福韦酯及苦参素26周,随后继续单用阿德福韦酯26周。单用组32例,单用阿德福韦酯10mg/d,疗程52周。定期检测丙氨酸氨基转氨酶(ALT)复常率,HBVDNA转阴率,HBeAg/抗HBe血清转换率,两组在治疗结束时进行疗效评价。结果:两组ALT复常率在12、26、52周差异无显著性(P>0.05)。联合组HBVDNA阴转率在12周时为19.4%,单用组为12.5%,两组比较差异无显著性(P>0.05),但在第26周(54.8%vs28.1%),52周(64.5%vs46.9%)时,两组比较差异有显著性(P<0.05)。联合组与单用组HBeAg/抗HBe血清转换率12周时无明显差异,在第26周(25.8%vs9.4%),52周(38.7%vs18.8%)时,两组比较差异有显著性(P<0.05)。两组治疗过程中,未发现明显副作用。结论:阿德福韦酯和苦参素联合治疗HBeAg阳性慢性乙型肝炎,安全性与...

A clinical study of adefovir dipivoxil in combination with matrine for treatment of hepatitis B e antigen positive patients with chronic hepatitis B

Abstract] Objective: To evaluate the effects and safety of adefovir dipivoxil (ADV) in combination with matrine on patients of hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB). Methods: Sixty-three patients with chronic hepatitis B who were positive for HBeAg were randomly put into two groups: the treatment group (n=31) and the control group (n=32). Patients in the treatment group were treated with adefovir dipivoxil (ADV) combining with matrine for 26 weeks, and then were under defovir dipivoxil (ADV) mono-therapy for more 26 weeks. The patients in the control group received adefovir dipivoxil (ADV) 10mg/d alone for 52 weeks. All patients were regularly received tests of liver function, hepatitis B virus makers and HBV DNA loads. Results: No significant differences were found of the alanine aminotransferase (ALT) normalization rate between two groups at week 12, 26, 52 (P>0.05). HBV DNA undetectable (defined as <1000 copies/ml) rate in the treatment group was 19.4%, and it was 12.5% in the control group at week 12. There is no difference between two groups (P>0.05). While at week 26 (54.8% vs 28.1%) and week 52 (64.5% vs 46.9%), HBV DNA undetectable rates in the treatment group were significantly greater than those in the control group (P<0.05). The same results were also seen in two groups on HBeAg loss and HBeAg seroconversion rate. There is no difference between two groups on HBeAg/Anti-HBe seroconversion rate at week 12 (P>0.05). While at week 26 (38.7% vs 9.4%) and week 52 (51.6% vs 25.0%), HBeAg/Anti-HBe seroconversion rates in the treatment group were significantly greater than those in the control group (P<0.05). During the treatment, no side effects were observed in the two groups. Conclusion: Therapy of adefovir dipivoxil (ADV) in combination with matrine on HBeAg positive CHB was safe and resulted in higher HBeAg/Anti-HBe seroconversion rate and HBV DNA undetectable rate.